Newron Pharma....Billig ,Billiger am Billigsten (Seite 24)

[SNH1E]

Antwort auf Beitrag Nr.: 75.634.106 von Marvelfreak am 17.04.24 12:03:52

Du kostest...Nerven

[Marvelfreak]

Schade das es Chavez in den Aufsichtsrat geschafft hat. Bedeutet wieder mehr Kosten auf lange Sicht.

[lalopot]

Macht das Sinn ?!? Wozu war das dann gut ?!? Ich verstehe die Zusammenhänge nicht

[Marvelfreak]

Sehr gut 👍. Das müsste der Grund gewesen sein.

[nanofisch]

Die Anträge der Tagesordnung des ausserordentlichen Teils der Versammlung wurden nicht zur Abstimmung gestellt, da das erforderliche Quorum nicht erreicht wurde.

Ausserordentlicher Teil
1. Vorschlag zur Änderung von Artikel 14 der Statuten. Damit zusammenhängende und sich daraus ergebende Beschlüsse.

2. Vorschlag zur Ermächtigung des Verwaltungsrats gemäss Art. 2443 des Codice Civile, in den nächsten 5 Jahren das Aktienkapital einmalig oder mehrmals um einen maximalen Nominalbetrag von 357.636,00 Euro zuzüglich eines eventuellen Agios mit oder ohne Optionsrecht gemäss Art. 2441, Absätze 1 und/ oder 4, erster und zweiter Teil, und/oder 5, 6 des Codice Civile. Damit zusammenhängende und sich daraus ergebende Beschlüsse.

3. Vorschlag zur Ermächtigung des Verwaltungsrats gemäss Art. 2443 des Codice Civile, in den nächsten 5 Jahren das Aktienkapital einmalig oder mehrmals für einen maximalen Nominalbetrag von 107.291,00 Euro zu erhöhen, zuzüglich eines eventuellen Agios, unter Ausschluss der Optionsrechte gemäss Art. 2441, Absätze 5, 6 und/oder 8 des Codice Civile, für einen oder mehrere Aktienoptionspläne. Damit zusammenhängende und sich daraus ergebende Beschlüsse.

[montirosa]

Aktienhandel

wird in kürze weiter gehen.

[Investfuchs]

hmmm, mal sehen ob das die News waren.... oder ob da noch was nachkommt

[Masterofthehouse]

Sorry deam85, du warst Sekundenbruchteile schneller bim Erstellen!

[Masterofthehouse]

Newron announces AGM 2024 results
Milan, Italy, April 17, 2024, 11:30 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announces that its shareholders approved all motions on the agenda for the ordinary part of the AGM 2024 held today. The motions on the agenda for the extraordinary part of the meeting were not put to vote, due to the required quorum not being reached.
Ulrich Köstlin, Chairman of the Board of Directors of Newron, commented: “We thank all our shareholders for their ongoing trust and longstanding support. Newron’s total available cash resources together with the initial proceeds deriving from the subscription agreement signed post-period will fund the Company’s planned development programs and operations well into 2025 and thus well beyond the current key value inflection points in our pipeline. Last but not least we welcome Margarita Chavez as newly elected, independent Board member; we are looking forward to working with her and are convinced that her more than 20 years of dealmaking expertise and leadership in the pharmaceutical industry will be considerably beneficial for Newron.”
About Newron Pharmaceuticals
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia. For more information, please visit: www.newron.com

[deam85]

Ad hoc announcement pursuant to Art. 53 LR
Newron announces AGM 2024 results
Milan, Italy, April 17, 2024, 11:30 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announces that its shareholders approved all motions on the agenda for the ordinary part of the AGM 2024 held today. The motions on the agenda for the extraordinary part of the meeting were not put to vote, due to the required quorum not being reached.
Ulrich Köstlin, Chairman of the Board of Directors of Newron, commented: “We thank all our shareholders for their ongoing trust and longstanding support. Newron’s total available cash resources together with the initial proceeds deriving from the subscription agreement signed post-period will fund the Company’s planned development programs and operations well into 2025 and thus well beyond the current key value inflection points in our pipeline. Last but not least we welcome Margarita Chavez as newly elected, independent Board member; we are looking forward to working with her and are convinced that her more than 20 years of dealmaking expertise and leadership in the pharmaceutical industry will be considerably beneficial for Newron.”